{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:15:31Z","timestamp":1782951331293,"version":"3.54.5"},"reference-count":117,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PROSNI -  Apoyo a la Mejora en las Condiciones de Producci\u00f3n SNI y SNCA","award":["PROSNI2021"],"award-info":[{"award-number":["PROSNI2021"]}]},{"name":"PROSNI-Apoyo a la Mejora en las Condiciones de Producci\u00f3n SNI y SNCA","award":["PROSNI2021"],"award-info":[{"award-number":["PROSNI2021"]}]},{"name":"PROSNI Apoyo a la Mejora en las Condiciones de Producci\u00f3n SNI y SNCA","award":["PROSNI2021"],"award-info":[{"award-number":["PROSNI2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The current global prevalence of heart failure is estimated at 64.34 million cases, and it is expected to increase in the coming years, especially in countries with a medium-low sociodemographic index where the prevalence of risk factors is increasing alarmingly. Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients. This connection points out new challenges both in the context of the pathophysiological mechanisms involved, as well as in the quality of life of affected individuals. A hallmark of heart failure is chronic activation of the renin-angiotensin-aldosterone system, especially marked by a systemic increase in levels of angiotensin-II, a peptide with pleiotropic activities. Drugs that target the renin-angiotensin-aldosterone system have shown promising results both in the prevention of secondary cardiovascular events in myocardial infarction and heart failure, including a lower risk of certain cancers in these patients, as well as in current cancer therapies; therefore, understanding the mechanisms involved in this complex relationship will provide tools for a better diagnosis and treatment and to improve the prognosis and quality of life of people suffering from these two deadly diseases.<\/jats:p>","DOI":"10.3390\/ijms22137106","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T12:03:27Z","timestamp":1625141007000},"page":"7106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["RAAS: A Convergent Player in Ischemic Heart Failure and Cancer"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7564-4877","authenticated-orcid":false,"given":"Texali C.","family":"Garcia-Gardu\u00f1o","sequence":"first","affiliation":[{"name":"Centro Universitario de Ciencias de la Salud, Instituto de Investigaci\u00f3n en Ciencias Biom\u00e9dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico"},{"name":"Doctorado en Gen\u00e9tica Humana, Departamento de Biolog\u00eda Molecular y Gen\u00f3mica, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-2797","authenticated-orcid":false,"given":"Jorge R.","family":"Padilla-Gutierrez","sequence":"additional","affiliation":[{"name":"Centro Universitario de Ciencias de la Salud, Instituto de Investigaci\u00f3n en Ciencias Biom\u00e9dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cambr\u00f3n-Mora","sequence":"additional","affiliation":[{"name":"Doctorado en Biolog\u00eda Molecular, Departamento de Biolog\u00eda Molecular y Gen\u00f3mica, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-022X","authenticated-orcid":false,"given":"Yeminia","family":"Valle","sequence":"additional","affiliation":[{"name":"Centro Universitario de Ciencias de la Salud, Instituto de Investigaci\u00f3n en Ciencias Biom\u00e9dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1113\/JP276746","article-title":"Mechanisms underlying the cross-talk between heart and cancer","volume":"598","author":"Brancaccio","year":"2020","journal-title":"J. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"658900","DOI":"10.3389\/fcvm.2021.658900","article-title":"Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs","volume":"8","author":"Papazoglou","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: A long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jjcc.2020.07.026","article-title":"Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study","volume":"77","author":"Kwak","year":"2021","journal-title":"J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer","volume":"62","author":"Hasin","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","article-title":"Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer","volume":"68","author":"Hasin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/hr.2017.45","article-title":"Does the pathophysiology of heart failure prime the incidence of cancer?","volume":"40","author":"Sakamoto","year":"2017","journal-title":"Hypertens. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10741-019-09876-0","article-title":"Does heart failure increase the risk of incident cancer? A meta-analysis and systematic review","volume":"25","author":"Zhang","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","article-title":"Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology","volume":"5","author":"Bertero","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/postgradmedj-2016-134045","article-title":"The renin-angiotensin-aldosterone system in heart failure for the non-specialist: The past, the present and the future","volume":"93","author":"Orsborne","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin\u2013angiotensin system in cardiovascular disease","volume":"17","author":"Riquelme","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: Old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1470320313496858","article-title":"The renin-angiotensin system meets the hallmarks of cancer","volume":"16","year":"2015","journal-title":"JRAAS J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_15","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation\/american heart association task force on practice guidelines","volume":"16","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"Lippi","year":"2020","journal-title":"AME Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/CIRCRESAHA.118.313568","article-title":"Medical Therapy for Heart Failure Caused by Ischemic Heart Disease","volume":"124","author":"Elgendy","year":"2019","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ. Res."},{"key":"ref_19","first-page":"e9349","article-title":"Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.002667","article-title":"Heart failure complicating acute myocardial infarction; burden and timing of occurrence: A nation-wide analysis including 86 771 patients from the cardiovascular disease in norway (CVDNOR) project","volume":"5","author":"Sulo","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4330\/wjc.v9.i5.407","article-title":"Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk","volume":"9","author":"Cahill","year":"2017","journal-title":"World J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart failure after myocardial infarction: Incidence and predictors","volume":"8","author":"Stehlik","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"23","author":"Groenewegen","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"ref_25","unstructured":"American Cancer Society (2021, June 27). Cancer Facts and Figures 2021. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2018.01.069","article-title":"Lack of Association Between Heart Failure and Incident Cancer","volume":"71","author":"Selvaraj","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1038\/s41598-018-19436-5","article-title":"Angiotensin II Overstimulation Leads to an Increased Susceptibility to Dilated Cardiomyopathy and Higher Mortality in Female Mice","volume":"8","author":"Mathieu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/aje\/kwv455","article-title":"Temporal trends in hospitalization for acute decompensated heart failure in the United States, 1998\u20132011","volume":"183","author":"Agarwal","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/eurheartj\/ehs154","article-title":"How to use high-sensitivity cardiac troponins in acute cardiac care","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-019-09855-5","article-title":"The renin-angiotensin-aldosterone system: A crossroad from arterial hypertension to heart failure","volume":"25","author":"Pugliese","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ziaja, M., Urbanek, K.A., Kowalska, K., and Piastowska-Ciesielska, A.W. (2021). Angiotensin II and Angiotensin Receptors 1 and 2\u2014Multifunctional System in Cells Biology, What Do We Know?. Cells, 10.","DOI":"10.3390\/cells10020381"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MNH.0b013e328350261b","article-title":"AT2 receptor agonists: Hypertension and beyond","volume":"21","author":"Steckelings","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fphar.2017.00564","article-title":"Anti-fibrotic potential of AT2 receptor agonists","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.109.147843","article-title":"Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor \u03bab","volume":"55","author":"Rompe","year":"2010","journal-title":"Hypertension"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sheikh, S.P. (2018). Angiotensin Type 2 Receptor. Encyclopedia of Signaling Molecules, Springer International Publishing.","DOI":"10.1007\/978-3-319-67199-4_451"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3892\/mmr.2017.6848","article-title":"The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.4049\/jimmunol.1000314","article-title":"Anti-Inflammatory Effects of the Activation of the Angiotensin-(1\u20137) Receptor, Mas, in Experimental Models of Arthritis","volume":"185","author":"Coelho","year":"2010","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2576-1471.1000134","article-title":"Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways","volume":"2","author":"Chappell","year":"2017","journal-title":"J. Cell Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.peptides.2016.03.017","article-title":"Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats","volume":"79","author":"Park","year":"2016","journal-title":"Peptides"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2174\/1389450121666200210124217","article-title":"ACE2\/Angiotensin-(1-7)\/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors","volume":"21","author":"Palmeira","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cca.2014.10.031","article-title":"Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible?","volume":"443","author":"Emdin","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurheartj\/ehaa995","article-title":"Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms","volume":"42","author":"Kyaw","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.regpep.2006.01.007","article-title":"Angiotensin II type 1 receptor expression on human leukocyte subsets: A flow cytometric and RT-PCR study","volume":"134","author":"Rasini","year":"2006","journal-title":"Regul. Pept."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/HYPERTENSIONAHA.115.06474","article-title":"Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells","volume":"67","author":"Kim","year":"2016","journal-title":"Hypertension"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II Drives the Production of Tumor-Promoting Macrophages","volume":"38","author":"Etzrodt","year":"2013","journal-title":"Immunity"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rudi, W.-S., Molitor, M., Garlapati, V., Finger, S., Wild, J., M\u00fcnzel, T., Karbach, S.H., and Wenzel, P. (2021). ACE Inhibition Modulates Myeloid Hematopoiesis after Acute Myocardial Infarction and Reduces Cardiac and Vascular Inflammation in Ischemic Heart Failure. Antioxidants, 10.","DOI":"10.3390\/antiox10030396"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/FJC.0000000000000003","article-title":"The immune system and the remodeling infarcted heart: Cell biological insights and therapeutic opportunities","volume":"63","author":"Frangogiannis","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2015.12.048","article-title":"Leukocytes link local and systemic inflammation in ischemic cardiovascular disease an expanded cardiovascular continuum","volume":"67","author":"Libby","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Baliga, R.R., and Haas, G.J. (2015). Mechanisms of Heart Failure BT\u2014Management of Heart Failure: Volume 1: Medical, Springer.","DOI":"10.1007\/978-1-4471-6657-3"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e003101","DOI":"10.1161\/JAHA.115.003101","article-title":"Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers","volume":"5","author":"Dewey","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2020.01399","article-title":"Systemic Reprogramming of Monocytes in Cancer","volume":"10","author":"Kiss","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2050312120965752","DOI":"10.1177\/2050312120965752","article-title":"Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer","volume":"8","author":"Amin","year":"2020","journal-title":"SAGE Open Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11906-010-0171-x","article-title":"Endothelial damage and regeneration: The role of the renin-angiotensin- aldosterone system","volume":"13","author":"Becher","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fphys.2020.01067","article-title":"Role of Renin-Angiotensin System Components in Atherosclerosis: Focus on Ang-II, ACE2, and Ang-1\u20137","volume":"11","author":"Silva","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_67","first-page":"97","article-title":"The endothelial mineralocorticoid receptor: Mediator of the switch from vascular health to disease","volume":"26","author":"Davel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_68","first-page":"3","article-title":"Targeting the Endothelium to Achieve Cardioprotection","volume":"12","author":"Lavandero","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/2047487319884246","article-title":"Assessment of peripheral endothelial function predicts future risk of solid-tumor cancer","volume":"27","author":"Toya","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ijc.28146","article-title":"Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis","volume":"133","author":"Franses","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cvr\/cvaa042","article-title":"Nox2+myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1","volume":"117","author":"Molitor","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Catarata, M.J., Ribeiro, R., Oliveira, M.J., Cordeiro, C.R., and Medeiros, R. (2020). Renin-angiotensin system in lung tumor and microenvironment interactions. Cancers, 12.","DOI":"10.3390\/cancers12061457"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","article-title":"The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis","volume":"151","author":"Ishikane","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.21037\/atm-20-5293","article-title":"Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma","volume":"9","author":"Feng","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e019390","DOI":"10.1161\/JAHA.120.019390","article-title":"Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"9","author":"Patel","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","article-title":"Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium","volume":"24","author":"Lutz","year":"2012","journal-title":"Cell. Signal."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40256-019-00343-7","article-title":"Renin\u2013Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study","volume":"19","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_78","first-page":"114","article-title":"Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction","volume":"73","author":"Saucedo","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15184","DOI":"10.1038\/s41598-020-72232-y","article-title":"Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization","volume":"10","author":"Sim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The potential therapeutic use of renin\u2013angiotensin system inhibitors in the treatment of inflammatory diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3389\/fphar.2020.610157","article-title":"The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9149(93)90520-M","article-title":"Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction","volume":"71","author":"Aronow","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1388-9842(99)00039-2","article-title":"Perindopril for elderly people with chronic heart failure: The PEP-CHF study","volume":"1","author":"Cleland","year":"1999","journal-title":"Eur. J. Heart Fail."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.166.6.659","article-title":"Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study","volume":"166","author":"Ferrari","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"(1993). The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342, 821\u2013828.","DOI":"10.1016\/0140-6736(93)92693-N"},{"key":"ref_87","first-page":"49","article-title":"A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"17","author":"Tepper","year":"1996","journal-title":"Cardiovasc. Rev. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators, Yusuf, S., Teo, K., Anderson, C., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., and Sleight, P. (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet, 372, 1174\u20131183.","DOI":"10.1016\/S0140-6736(08)61242-8"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ebm.9.2.44","article-title":"Candesartan reduced mortality and hospital admissions in chronic heart failure","volume":"9","author":"Pfeffer","year":"2004","journal-title":"Evid. Based. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1067\/mhj.2000.108832","article-title":"Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design","volume":"140","author":"Pfeffer","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_93","first-page":"425","article-title":"Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction","volume":"3","author":"Bissessor","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","article-title":"The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis","volume":"26","author":"Song","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"117181","DOI":"10.1016\/j.lfs.2019.117181","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis","volume":"242","author":"Asgharzadeh","year":"2020","journal-title":"Life Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e19075","DOI":"10.1097\/MD.0000000000019075","article-title":"The renin\u2013angiotensin system blockers and survival in digestive system malignancies","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","article-title":"Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: A meta-analysis of randomized controlled trials","volume":"26","author":"Fang","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/00029330-200811010-00012","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model","volume":"121","author":"Wang","year":"2008","journal-title":"Chin. Med. J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Rasha, F., Kahathuduwa, C., Ramalingam, L., Hernandez, A., Moussa, H., and Moustaid-Moussa, N. (2020). Combined Effects of Eicosapentaenoic Acid and Adipocyte Renin\u2013Angiotensin System Inhibition on Breast Cancer Cell Inflammation and Migration. Cancers, 12.","DOI":"10.3390\/cancers12010220"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.leukres.2008.09.029","article-title":"Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents","volume":"33","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Matsui, T., Chiyo, T., Kobara, H., Fujihara, S., Fujita, K., Namima, D., Nakahara, M., Kobayashi, N., Nishiyama, N., and Yachida, T. (2019). Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133197"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2007.00025.x","article-title":"Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer","volume":"20","author":"Kosugi","year":"2007","journal-title":"Hum. Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.yexcr.2018.04.022","article-title":"Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux","volume":"368","author":"Rasheduzzaman","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.4049\/jimmunol.1800619","article-title":"The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment","volume":"202","author":"Regan","year":"2019","journal-title":"J. Immunol."},{"key":"ref_106","first-page":"927","article-title":"The therapeutic potential of losartan in lung metastasis of colorectal cancer","volume":"19","author":"Hashemzehi","year":"2020","journal-title":"EXCLI J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/s41388-018-0654-9","article-title":"Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response","volume":"38","author":"Gold","year":"2019","journal-title":"Oncogene"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1179546819866445","article-title":"Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin. Med. Insights Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Tini, G., Bertero, E., Signori, A., Sormani, M.P., Maack, C., De Boer, R.A., Canepa, M., and Ameri, P. (2020). Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc., 9.","DOI":"10.1161\/JAHA.119.016309"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: A promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0401-3","article-title":"Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy","volume":"6","author":"Xie","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fphar.2020.566401","article-title":"Next-Generation Immunotherapies to Improve Anticancer Immunity","volume":"11","author":"Shi","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:49Z","timestamp":1760163889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":117,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22137106"],"URL":"https:\/\/doi.org\/10.3390\/ijms22137106","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}